Loading stock data…
Eton Pharmaceuticals, Inc. (ETON)
$59.34+0.90 (+1.53%)
Market ClosedLast close Sep 8
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eton Pharmaceuticals, Inc. in the Healthcare sector is trading at $59.34 with a market capitalization of $1.7B. Wall Street consensus targets $71.00 (4 analysts), implying a +19.6% move over the next 12 months. The stock is currently near its 52-week high of $66.37, remaining 108.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +19.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $24.27M↑ | $21.28M↓ | $22.46M↑ | $18.93M↑ | $17.28M |
| Gross Profit | $14.73M↑ | $13.10M↑ | $7.86M↓ | $11.92M↑ | $9.86M |
| Operating Income | $2.41M↓ | $2.46M↑ | -$1.36M↑ | -$1.48M↓ | -$470,000 |
| Net Income | $1.55M↑ | $1.48M↑ | -$1.93M↑ | -$2.58M↓ | -$1.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
152.17
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.24%
Volume
Today's trading volume
396,004
Recent News
Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)
During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said: I think you take […]
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.
Three Biotech Stocks Stick Out With Their Stellar Charts
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.
Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript
Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth.
Is Eton Pharmaceuticals (ETON) Fully Priced On Strong Q2 Results And Raised Guidance?
Eton Pharmaceuticals (ETON) has become a focus for investors after its second quarter 2026 report, which showed US$37.59 million in revenue, US$11.58 million in net income, and a shift from loss to earnings per share. See our latest analysis for Eton Pharmaceuticals. The strong Q2 results and raised 2026 guidance have coincided with a sharp re-rating in Eton Pharmaceuticals, with a 1 day share price return of 44.26% helping extend its year to date share price return to 261.99%, while the 3...